Tocagen to Report First Quarter 2018 Financial Results on Thursday, May 10

Tocagen to Report First Quarter 2018 Financial Results on Thursday, May 10

PR Newswire

SAN DIEGO, May 3, 2018 /PRNewswire/ -- Tocagen Inc. TOCA, a clinical-stage, cancer-selective gene therapy company, today announced it will report its first quarter 2018 financial results and business progress on Thursday, May 10, 2018, after the close of the U.S. financial markets.

Tocagen Inc. (PRNewsfoto/Tocagen Inc.)

To receive Tocagen's press releases and other investor information, please visit the Investor Relations page of the company's website and register for email alerts.

About Tocagen

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen's lead investigational product candidate, Toca 511 & Toca FC, is under evaluation in a pivotal Phase 3 trial for recurrent high grade glioma (HGG), a disease with significant unmet medical need. The U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of recurrent HGG and the European Medicines Agency (EMA) has granted Toca 511 PRIME (PRIority MEdicines) designation for the treatment of glioma. For more information about Tocagen, visit www.tocagen.com.

Media Contact:

Monica May

Canale Communications

(619) 849-5383

monica@canalecomm.com

Investor Contact:

Gitanjali Jain Ogawa

Solebury Trout

(646) 378-2949

Gogawa@troutgroup.com

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/tocagen-to-report-first-quarter-2018-financial-results-on-thursday-may-10-300642341.html

SOURCE Tocagen Inc.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press ReleasesConference Call Announcements
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!